Segment Reporting

3 Months Ended

Mar. 31, 2013

Segment Reporting

12. Segment Reporting

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s principal operating segment.

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):

	Three months ended March 31,
	2013			2012
United States		47	%		36	%
Sweden		39	%		43	%
United Kingdom		12	%		14	%
Other		2	%		7	%
		100	%		100	%

Revenue from significant customers as a percentage of the Company’s total revenue is as follows:

	Three months ended March 31,
	2013			2012
Orencia® Royalties from Bristol		24	%		24	%
Bioprocessing Customer A		38	%		43	%
Bioprocessing Customer B		12	%		14	%
Bioprocessing Customer C		15	%		—

Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties receivable balances are as follows:

	March 31, 2013			December 31, 2012
Orencia® Royalties from Bristol		36	%		31	%
Bioprocessing Customer A		36	%		21	%
Pfizer		—			38	%